Berlin - Delayed Quote EUR
AbCellera Biologics Inc (8QQ.BE)
2.5800
-0.1940
(-6.99%)
At close: June 13 at 8:08:05 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
23,114
28,833
38,025
485,424
375,203
Cost of Revenue
--
0
0
66,436
45,516
Gross Profit
--
28,833
38,025
418,988
329,687
Operating Expense
331,148
329,979
261,077
191,923
107,788
Operating Income
-308,034
-301,146
-223,052
227,065
221,899
Net Non Operating Interest Income Expense
36,123
38,473
42,247
16,079
3,330
Other Income Expense
61,279
62,278
6,776
-4,045
-6,080
Pretax Income
-210,632
-200,395
-174,029
239,099
219,149
Tax Provision
-42,764
-37,538
-27,631
80,580
65,685
Net Income Common Stockholders
-167,868
-162,857
-146,398
158,519
153,464
Diluted NI Available to Com Stockholders
-167,868
-162,857
-146,398
158,519
153,464
Basic EPS
-0.56
-0.55
-0.51
0.56
0.56
Diluted EPS
-0.56
-0.55
-0.51
0.50
0.48
Basic Average Shares
295,569.7220
294,327.5320
289,166.4860
285,056.6060
275,763.7450
Diluted Average Shares
295,569.7220
294,327.5320
289,166.4860
314,827.2550
318,294.2360
Total Operating Income as Reported
-322,532
-314,766
-237,207
216,511
204,413
Total Expenses
331,148
329,979
261,077
258,359
153,304
Net Income from Continuing & Discontinued Operation
-167,868
-162,857
-146,398
158,519
153,464
Normalized Income
-167,868
-162,857
-146,398
158,519
153,464
Interest Income
36,123
38,473
42,247
16,079
3,330
Interest Expense
--
--
--
4,045
5,225
Net Interest Income
36,123
38,473
42,247
16,079
3,330
EBIT
-308,034
-301,146
-223,052
227,065
221,899
EBITDA
-211,197
-204,148
-192,158
260,167
239,149
Reconciled Cost of Revenue
--
0
0
61,177
42,717
Reconciled Depreciation
96,837
96,998
30,894
33,102
17,250
Net Income from Continuing Operation Net Minority Interest
-167,868
-162,857
-146,398
158,519
153,464
Total Unusual Items Excluding Goodwill
--
--
--
--
-855
Total Unusual Items
--
--
--
--
-855
Normalized EBITDA
-211,197
-204,148
-192,158
260,167
239,149
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 12/23/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BT3.BE Lineage Cell Therapeutics Inc
0.5850
-0.85%
AB3A.MU Sarepta Therapeutics Inc
31.82
-1.18%
GXE.F Galapagos NV
24.76
+0.08%
ITRX inTerra Resources Corp
0.0240
0.00%
GENSY Genus plc
24.34
0.00%
ONCIN.OL Oncoinvent ASA
1.8500
-8.64%
AYJ.HA Valneva SE
2.6180
-4.10%
300759.SZ Pharmaron Beijing Co., Ltd.
24.84
-2.47%
UNC.F UCB SA
160.85
-1.44%
T3X.BE Telix Pharmaceuticals Ltd
13.93
-5.63%